United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Whitestone REIT (WSR) Q2 2024 Earnings Call Transcript

Bristol-Myers

Johnson & Johnson

McDonald's

Altria

NextEra Energy

NEXTracker Inc

The market consistently offers opportunities in value stocks for bargain hunters willing to do the work and take risks. Most of the work is done here for you as I have identified value stocks that are cheaply priced.

Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore

British American Tobacco

Philip Morris

Verizon

Fed Chairman Jerome Powell hinted at a possible rate cut at the September meeting, reinforcing investor expectations. Powell expresses confidence in achieving a soft landing, as inflation trends towards the 2% target. These are 3 high-yield dividend stocks which should benefit.

Fed Signals Likely Rate Cuts In September: Buy These 3 High-Yield Blue-Chip Stocks Today

Blackstone Secured Lending Fund

Tesla

Alphabet and Tesla had negative reactions to Q2 earnings reports. Economic data showed PCE increased 0.1% MoM, while consumer confidence declined for the 4th consecutive month. The Dividend Harvesting Portfolio had another positive week, reaching new highs in dividend income.

Dividend Harvesting Portfolio Week 178: $17,800 Allocated, $1,612.87 In Projected Dividends

Archer-Daniels-Midland Company

Bank of America

Bank of New York Mellon

Citizens Financial Group

Comerica

Comcast

CVS Health

Fifth Third Bancorp

JPMorgan Chase & Co

Morgan Stanley

M&T Bank

Bank OZK

PNC Financial Services

Prudential Financial

Synchrony Financial

U.S. stocks typically do especially well during August in presidential election years like this one. On average since its inception in 1896, the Dow Jones Industrial Average DJIA has gained 2.8% in August of a presidential election year.

16 stocks to exploit August's explosive election-year gains

I initiated a "Buy" rating on Pfizer stock in February 2024, and since then, it's aging well. I believe the recovery rally in PFE stock may be just the beginning. The cost management initiatives seem to be progressing faster and more efficiently than one would have thought a few quarters ago - the solid Q2 numbers show that. Wall Street analysts are still giving very modest EPS growth projections for the next few years, creating a ground for possible EPS beating in the next quarters.

Pfizer Stock: It May Be Just The Beginning Of A Solid Rally

Pfizer's management is committed to maintaining and growing the dividend. The big drugmaker's dividend should be even more secure thanks to coming bottom-line improvements.

Pfizer Just Confirmed It's a Dividend Investor's Dream Stock

CEO Albert Bourla doesn't see the company making a big acquisition for a GLP-1 drugmaker. Pfizer has close to $70 billion in long-term debt on its books.

Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening

Pfizer's earnings soared earlier in the pandemic, thanks to its blockbuster coronavirus vaccine and treatment. Since, revenue has dropped -- but Pfizer has made major efforts to return to growth.

Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?

Apple

Deckers Outdoor

Disney

Novo Nordisk

PayPal

Catalysts are forming around a lot of the top stocks right now, making this a good time for investors to buy. Many companies are seeing a boost in their share price following strong earnings reports.

The Top 7 Stocks to Buy Now: Summer 2024

On Tuesday, Pfizer Inc. PFE reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.

Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns

Merck

The prime culprit for yesterday's 9.8% drop in Merck was what seemed to be a rather slight slip in Gardasil revenue – Merck's HPV vaccine – which came in about $20 million below consensus. At $113 – $115 per share, MRK is now trading at 14x and 12x 2024 and 2025 consensus estimates for expected growth this year that compares to '22 $7.48 in EPS. Pfizer reported a good quarter yesterday, with a 2% revenue beat and a 30% EPS for y-o-y growth of 2%, 9% operating income growth and -2% decline in EPS.

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Pfizer (PFE) shares rose Tuesday after the pharmaceutical giant beat second-quarter revenue expectations and raised its full-year guidance.

Pfizer Posts First Quarterly Revenue Growth Since Peak COVID Vaccine Sales

Pfizer Inc. (PFE) Q2 2024 Earnings Call Transcript

Pfizer boosted its full-year guidance for both revenue and earnings. Its oncology segment saw significant growth, driven by the recent acquisition of Seagen.

Pfizer's Upgraded Oncology Segment Powers Second-Quarter Growth

Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them.

Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.

Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know

The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Tuesday.

Dow Jumps 200 Points; Pfizer Earnings Top Views

Pharmaceutical giants Merck & Co Inc  (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results.

Options Traders Blast 2 Pharma Socks After Earnings

Pfizer (PFE) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.67 per share a year ago.

Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates

Drugmaker Pfizer reported quarterly earnings above expectations on Tuesday as it raised full year guidance on the back of strong sales of non-Covid products.

Pfizer Stock Rises After Guidance Hike, Earnings Beat.

Pfizer Inc's (NYSE:PFE, ETR:PFE) stock is up ahead of the bell after the company raised its annual profit forecast following stronger-than-expected sales of its Covid vaccine and antiviral treatment. The drugmaker now anticipates an annual profit of $2.45 to $2.65 per share, up from its previous forecast of $2.15 to $2.35 per share.

News for Pfizer Stock (PFE)